- Previous Close
1.4900 - Open
1.4800 - Bid 1.3100 x 100
- Ask 1.4200 x 100
- Day's Range
1.2800 - 1.4800 - 52 Week Range
1.0700 - 6.3500 - Volume
260,825 - Avg. Volume
381,176 - Market Cap (intraday)
89.126M - Beta (5Y Monthly) 0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3900 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.14
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
zurabio.comRecent News: ZURA
View More
Performance Overview: ZURA
Trailing total returns as of 3/26/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZURA
View MoreValuation Measures
Market Cap
97.29M
Enterprise Value
97.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.61%
Return on Equity (ttm)
-43.75%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-45.39M
Diluted EPS (ttm)
-0.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
176.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-24.76M
Research Analysis: ZURA
View MoreCompany Insights: ZURA
ZURA does not have Company Insights